Japan Rebound For Amgen With Daiichi Biosimilars Deal
Executive Summary
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.